EG 427 has announced the successful closing of a €27 million Series B financing round co-led by Andera Partners and Bpifrance – as part of the InnoBio investment strategy. The proceeds from the financing will be used to fund the Phase Ib/IIa development of EG 427’s lead genetic medicine product, EG110A, for the treatment of […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!